What is Sentio BioSciences?
Sentio BioSciences operates as a specialized pharmaceutical entity with a dual focus on human and animal health. The company distinguishes itself through a comprehensive service model that integrates research and development with cGMP manufacturing and rigorous regulatory compliance. As a Contract Development and Manufacturing Organization (CDMO), Sentio provides essential infrastructure for the commercialization of complex medicines. With over 15 years of industry experience, the firm is a vital contributor to the resilience of the United States pharmaceutical supply chain, offering licensing and collaborative frameworks that support innovators in bringing critical therapies to market.
How much funding has Sentio BioSciences raised?
Sentio BioSciences has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Sentio BioSciences
PPP
Public-Private Partnership
What's next for Sentio BioSciences?
With the successful acquisition of this capital, Sentio BioSciences is poised to scale its manufacturing footprint and deepen its commitment to workforce development. The strategic roadmap focuses on enhancing cGMP production capabilities to meet the rising demand for domestic pharmaceutical manufacturing. By prioritizing professional growth and operational excellence, the company aims to further integrate itself into the global supply chain, providing a reliable partner for innovators seeking to navigate the complexities of drug development and regulatory approval. Future initiatives will likely center on expanding service offerings and strengthening the infrastructure required to support the next generation of essential medicines.
See full Sentio BioSciences company page
